Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 17(7): e0270910, 2022.
Article in English | MEDLINE | ID: mdl-35839216

ABSTRACT

Hepatitis C virus (HCV) infections are public health problem across the globe, particularly in developing countries. Pakistan has the second highest prevalence of HCV infection worldwide. Limited data exist from Pakistan about persons who inject drugs (PWID) and are at significant risk of exposure to HCV infection and transmission. Serum specimens (n = 110) collected from PWID residing in four provinces were tested for molecular markers of HCV infection. Next generation sequencing (NGS) of the hypervariable region (HVR1) of HCV and Global Hepatitis Outbreak and Surveillance Technology (GHOST) were used to determine HCV genotype, genetic heterogeneity, and construct transmission networks. Among tested specimens, 47.3% were found anti-HCV positive and 34.6% were HCV RNA-positive and belonged to four genotypes, with 3a most prevalent followed by 1a, 1b and 4a. Variants sampled from five cases formed phylogenetic cluster and a transmission network. One case harbored infection with two different genotypes. High prevalence of infections and presence of various genotypes indicate frequent introduction and transmission of HCV among PWID in Pakistan. Identification of a transmission cluster across three provinces, involving 20% of all cases, suggests the existence of a countrywide transmission network among PWIDs. Understanding the structure of this network should assist in devising effective public health strategies to eliminate HCV infection in Pakistan.


Subject(s)
Drug Users , Hepatitis C , Substance Abuse, Intravenous , Genotype , Hepacivirus/genetics , Humans , Pakistan/epidemiology , Phylogeny , Prevalence , Substance Abuse, Intravenous/epidemiology
2.
Clin Chem ; 59(9): 1357-68, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23676310

ABSTRACT

BACKGROUND: There are 45 known genetic diseases that impair the lysosomal degradation of macromolecules. The loss of a single lysosomal hydrolase leads to the accumulation of its undegraded substrates in tissues and increases of related glycoconjugates in urine, some of which can be detected by screening of free oligosaccharides (FOS) in urine. Traditional 1-dimensional TLC for urine oligosaccharide analysis has limited analytical specificity and sensitivity. We developed fast and robust urinary FOS and glycoaminoacid analyses by MALDI-time-of-flight/time-of-flight (MALDI-TOF/TOF) mass spectrometry for the diagnosis of oligosaccharidoses and other lysosomal storage diseases. METHODS: The FOS in urine equivalent to 0.09 mg creatinine were purified through sequential passage over a Sep-Pak C18 column and a carbograph column and were then permethylated. MALDI-TOF/TOF was used to analyze the permethylated FOS. We studied urine samples from individuals in 7 different age groups ranging from 0-1 months to ≥ 17 years as well as urine from known patients with different lysosomal storage diseases. RESULTS: We identified diagnostic urinary FOS patterns for α-mannosidosis, galactosialidosis, mucolipidosis type II/III, sialidosis, α-fucosidosis, aspartylglucosaminuria (AGU), Pompe disease, Gaucher disease, and GM1 and GM2 gangliosidosis. Interestingly, the increase in urinary FOS characteristic of lysosomal storage diseases relative to normal FOS appeared to correlate with the disease severity. CONCLUSIONS: The analysis of urinary FOS by MALDI-TOF/TOF is a powerful tool for first-tier screening of oligosaccharidoses and lysosomal storage diseases.


Subject(s)
Lysosomal Storage Diseases/diagnosis , Lysosomal Storage Diseases/urine , Oligosaccharides/urine , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Adolescent , Aspartylglucosaminuria/diagnosis , Aspartylglucosaminuria/urine , Child , Child, Preschool , Female , Fucosidosis/diagnosis , Fucosidosis/urine , Gangliosidoses, GM2/diagnosis , Gangliosidoses, GM2/urine , Gangliosidosis, GM1/diagnosis , Gangliosidosis, GM1/urine , Gaucher Disease/diagnosis , Gaucher Disease/urine , Glycogen Storage Disease Type II/diagnosis , Glycogen Storage Disease Type II/urine , Humans , Infant , Infant, Newborn , Male , Mannosidase Deficiency Diseases/diagnosis , Mannosidase Deficiency Diseases/urine , Mucolipidoses/diagnosis , Mucolipidoses/urine
SELECTION OF CITATIONS
SEARCH DETAIL